Orna Levran

Dr. Orna Levran

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2008 in Genes, Brain and Behavior
Verified
Journal Article
Open access
PDF file
OLOrna Levran
Orna Levran
DLD. Londono
D. Londono
KOK. O’hara
K. O’hara
DNDavid Nielsen
David Nielsen
EPE. Peles
E. Peles
MKM. J. Kreek
M. J. Kreek
Heroin addiction is a chronic complex disease with a substantial genetic contribution. This study was designed to identify genetic variants that are associated with susceptibility to develop heroin addiction by analyzing 1350 variants in 130 candidate genes. All subjects had Caucasian ancestry. The sample consisted of 412 former severe heroin addicts in methadone treatment, and 184 healthy controls with no history of drug abuse. Nine variants, in six genes, showed the lowest nominalPvalues in the association tests (P < 0.01). These variants were in noncoding regions of the genes encoding the mu (OPRM1; rs510769 and rs3778151), kappa (OPRK1; rs6473797) and delta (OPRD1; rs2236861, rs2236857 and rs3766951) opioid receptors; the neuropeptide galanin (GAL; rs694066); the serotonin receptor subtype 3B (HTR3B; rs3758987) and the casein kinase 1 isoform epsilon (CSNK1E; rs1534891). Several haplotypes and multilocus genotype patterns showed nominally significant associations (e.g.OPRM1;P = 0.0006 andCSNK1E;P = 0.0007). Analysis of a combined effect ofOPRM1andOPRD1showed that rs510769 and rs2236861 increase the risk of heroin addiction (P = 0.0005). None of these associations remained significant after adjustment for multiple testing. This study suggests the involvement of several genes and variants in heroin addiction, which is worthy of future study.

17 April 2008 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
OLOrna Levran
Orna Levran
KOKimberly O'HAra
Kimberly O'HAra
EPEinat Peles
Einat Peles
DLDawei Li
Dawei Li
SBSandra Barral
Sandra Barral
MKMary Jeanne Kreek
Mary Jeanne Kreek
Methadone is a mu-opioid receptor agonist used for treating opiate dependence. The range of effective methadone doses is broad. Part of the large inter-individual variability in efficacy may be accounted for by genetic factors. Methadone is a substrate of the transporter P-glycoprotein (P-gp) 170 that is encoded by the ABCB1 (MDR1) gene. Thus, P-gp variants may play a role in methadone absorption and distribution. We assessed the association between ABCB1 polymorphisms and methadone dose requirements in 98 methadone-maintained patients. The stabilizing methadone doses were normally distributed with a mean and median dose of 160 mg/day (range 30–280 mg/day). Statistical analysis showed significant difference in genotype frequencies between the ‘higher’ (>150 mg/day) and ‘lower’ (≤150 mg/day) methadone dose groups for single nucleotide polymorphism (SNP) 1236C>T (rs1128503) (experiment-wise P = 0.0325). Furthermore, individuals bearing the 3-locus genotype pattern TT-TT-TT (rs1045642, rs2032582 and rs1128503) have an approximately 5-fold chance of requiring the ‘higher’ methadone dose, while individuals heterozygous for these three SNPs have an approximately 3-fold chance of stabilizing at the ‘lower’ methadone dose (point-wise P-value = 0.026). These data suggest that specific ABCB1 variants may have clinical relevance by influencing the methadone dose required to prevent withdrawal symptoms and relapse in this population.

1 May 2012 in Human Genetics
Verified
Journal Article
Closed access
PDF file
OLOrna Levran
Orna Levran
VYVadim Yuferov
Vadim Yuferov
MKMary Jeanne Kreek
Mary Jeanne Kreek

25 July 2011 in Addiction Biology
Verified
Journal Article
Closed access
PDF file
OLOrna Levran
Orna Levran
EPEinat Peles
Einat Peles
SHSara Hamon
Sara Hamon
MRMatthew Randesi
Matthew Randesi
MAMiriam Adelson
Miriam Adelson
MKMary Jeanne Kreek
Mary Jeanne Kreek

15 July 2009 in Genes, Brain and Behavior
Verified
Journal Article
Open access
PDF file
OLOrna Levran
Orna Levran
DLD. Londono
D. Londono
KOK. O'HAra
K. O'HAra
MRM. Randesi
M. Randesi
JRJ. Rotrosen
J. Rotrosen
MKM. J. Kreek
M. J. Kreek
Heroin addiction is a chronic complex disease with a substantial genetic contribution. This study was designed to identify gene variants associated with heroin addiction in African Americans. The emphasis was on genes involved in reward modulation, behavioral control, cognitive function, signal transduction and stress response. We have performed a case–control association analysis by screening with 1350 variants of 130 genes. The sample consisted of 202 former severe heroin addicts in methadone treatment and 167 healthy controls with no history of drug abuse. Single nucleotide polymorphism (SNP), haplotype and multi‐SNP genotype pattern analyses were performed. Seventeen SNPs showed point‐wise significant association with heroin addiction (nominal P< 0.01). These SNPs are from genes encoding several receptors: adrenergic (ADRA1A), arginine vasopressin (AVPR1A), cholinergic (CHRM2), dopamine (DRD1), GABA‐A (GABRB3), glutamate (GRIN2A) and serotonin (HTR3A) as well as alcohol dehydrogenase (ADH7), glutamic acid decarboxylase (GAD1 and GAD2), the nucleoside transporter (SLC29A1) and diazepam‐binding inhibitor (DBI). The most significant result of the analyses was obtained for the GRIN2A haplotype G‐A‐T (rs4587976‐rs1071502‐rs1366076) with protective effect (Puncorrected = 9.6E‐ 05, Pcorrected = 0.058). This study corroborates several reported associations with alcohol and drug addiction as well as other related disorders and extends the list of variants that may affect the development of heroin addiction. Further studies will be necessary to replicate these associations and to elucidate the roles of these variants in drug addiction vulnerability.

1 July 2014 in Psychoneuroendocrinology
Verified
Journal Article
Closed access
OLOrna Levran
Orna Levran
EPE. Peles
E. Peles
MRM. Randesi
M. Randesi
YLY. Li
Y. Li
JRJ. Rotrosen
J. Rotrosen
MKM.J. Kreek
M.J. Kreek